FOLH1 and neoplasm: In contrast to our data, Lückerath et al. did not observe additional tumor growth retardation through the combined enzalutamide/PSMA-RLT treatment in mice bearing CRPC compared to mono-PSMA-RLT, despite significantly greater DNA damage and the persistent increase of PSMA expression [12].